MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies

Abstract

The use of magnetic resonance imaging (MRI) in multiple sclerosis (MS) has increased in our understanding of the natural history of the disease course and has provided and important tool for the analysis of new experimental therapies. Studies using MRI as well as pathological studies of MS indicate that the first event in the development of a new MS lesion as seen on T2 weighted images is disruption of the blood brain barrier (BBBD) which can be demonstrated by areas of increased signal on T1 weighted images done after the administration of gadolinium DTPA When GdDTPA enhanced MRIs are used to monitor disease activity in patients with mild relapsing remitting MS, a considerable degree of disease activity is observed in clinically stable patients. These findings indicate that MS is an active and progressive disease in most patients even during the earliest phases of the disease and before significant clinical disability has occurred. MRI is also an important tool in evaluating new therapies. Using simple baseline vs treatment designs evidence for an effect of a new treatment on MRI parameters such as Gd-DTPA enhanced measure of BBBD can be achieved using a small study cohort and over a short duration. Together these advances should lead to more rapid progress in the understanding of MS and in identifying new treatments.

Keywords

Multiple sclerosis MRI drug therapy inerferon-beta clinical trials

Get full access to this article

View all access options for this article.

References

1 Miller DH , Barkhoff , Nauta JJ . (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1077–1094.

2 Thompson AJ et al. (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 60–63.

3 Harris JO et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 548–555.

4 Wiebe S et al. (1992) Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol 643–650.

5 Barkhoff et al. (1992) Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. Am J Roentgenol 1041–1047.

6 Willoughby EW et al. (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 43–49.

7 Nauta JJ , Thompson AJ , Barkhoff , Miller DH . (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 6–14.

8 McFarland HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 758–766.

9 Koopmans RA et al. (1989) The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology 959–963.

10.

10 Kermode AG et al. (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1477–1489.

11.

11 Isaac C et al. (1988) Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1511–1515.

12.

12 Frank JA et al. (1994) Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol S86–S90.

13.

13 Stone LA et al. (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 611–619.

14.

14 Issac C , Li D , Genton M . (1988) Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1511–1515.

15.

15 Grossman RI et al. (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 117–122.

16.

16 Stone LA et al. (1995) Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age. Neurology 1122–1126.

17.

17 Smith ME et al. (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 480–489.

18.

18 Filippi M et al. (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 635–641.

19.

19 Paty DW , Li DK . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group [see comments]. Neurology 662–667.

20.

20 Stone LA et al. (1995) Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1808–1814.

21.

21 Whitaker JN , McFarland HF , Rudge P , Reingold S . (1996) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1–8.

22.

22 Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines [see comments]. J Neurol Neurosurg Psychiatry 683–688.

23.

23 Miller DH et al. (1996) Guidelines for the use of Magnetic Resonance techniques in monitoring the treatment of Multiple Sclerosis. Ann Neurol 6–16.